Idera Pharmaceuticals to Participate in a Panel Discussion at the Piper Jaffray GenomeRx Symposium
June 17 2014 - 8:00AM
Business Wire
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical stage
biopharmaceutical company developing nucleotide therapeutics for
patients with cancer and orphan diseases, today announced that
Sudhir Agrawal, D. Phil., Chief Executive Officer, will participate
in a panel discussion entitled “RNA/DNA: Getting It Where You Need
It” at the Piper Jaffray GenomeRx Symposium on Monday, June 23,
2014. The panel is scheduled to begin at 3:30 p.m. EDT and will
take place in New York City.
About Idera Pharmaceuticals, Inc.Idera Pharmaceuticals is
a clinical-stage biopharmaceutical company developing a novel
therapeutic approach for the treatment of genetically defined forms
of B-cell lymphoma and orphan autoimmune diseases. Idera’s
proprietary technology involves creating novel nucleic acid
therapeutics designed to inhibit over-activation of Toll-like
Receptors (TLRs). In addition to its TLR programs, Idera is
developing gene silencing oligonucleotides (GSOs) that it has
created using its proprietary technology to inhibit the production
of disease-associated proteins by targeting RNA.
Idera Pharmaceuticals, Inc.Sarah Carmody,
617-679-5552scarmody@iderapharma.com
Idera Pharmaceuticals (NASDAQ:IDRA)
Historical Stock Chart
From Apr 2024 to May 2024
Idera Pharmaceuticals (NASDAQ:IDRA)
Historical Stock Chart
From May 2023 to May 2024